婴幼儿室上性心动过速药物治疗疗程管理及相关因素  

Management of Treatment Duration and Associated Factors in Pharmacotherapy for Supraventricular Tachycardia in Infants and Young Children

作　　者：陈莉 杨艳峰 CHEN Li;YANG Yanfeng(Department of Pediatric Cardiology,Chengdu Women’s and Children’s Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 611731,Sichuan,China)

机构地区：[1]电子科技大学医学院附属妇女儿童医院成都市妇女儿童中心医院心内科,四川成都611731

出　　处：《心血管病学进展》2025年第4期310-313,共4页Advances in Cardiovascular Diseases

摘　　要：婴幼儿室上性心动过速反复持续发作可能导致严重心功能不全,现有临床指南推荐长期药物治疗,但治疗周期与危险分层的关系仍需进一步探讨。具有特定临床特征的患儿群体表现出显著增高的复发风险,明确相关因素可以对患儿进行复发风险评估,并确定低复发风险的人群。对低复发风险患儿给予4~6个月短期药物干预策略,在维持等效复发控制率的同时,可显著降低药物相关不良事件发生率。Recurrent and persistent episodes of supraventricular tachycardia in infants and young children may lead to severe cardiac dysfunction.Although current clinical guidelines recommend long-term pharmacological management,the correlation between treatment duration and risk stratification requires further investigation.Specific pediatric populations with distinct clinical characteristics demonstrate substantially elevated recurrence risks.Identification of these predictive factors enables precise recurrence risk evaluation and facilitates the delineation of low-risk subgroups.For patients stratified as low recurrence risk,implementing a 4 to 6 months short-term pharmacological intervention strategy achieves equivalent recurrence control rates while significantly reducing the incidence of drug-related adverse events compared with extended treatment protocols.

关 键 词：室上性心动过速 婴幼儿 药物治疗 疗程管理 影响因素 

分 类 号：R725.4[医药卫生—儿科]